Current status of nanomaterial-based treatment for hepatocellular carcinoma

被引:90
作者
Baig, Badriya [1 ]
Halim, Sulafa Abdel [2 ]
Farrukh, Aaminah [1 ]
Greish, Yaser [2 ]
Amin, Amr [1 ]
机构
[1] UAE Univ, Dept Biol, Al Ain, U Arab Emirates
[2] UAE Univ, Dept Chem, Al Ain, U Arab Emirates
关键词
Hepatic carcinoma; Nanoparticles; Synthetic nanoparticles; Natural nanoparticles; Surface functionalization; MESOPOROUS SILICA NANOPARTICLES; SERUM-ALBUMIN NANOPARTICLES; IRON-OXIDE NANOPARTICLES; NANO-ANTIOXIDANT THERAPY; DRUG-DELIVERY SYSTEM; CARBON NANOTUBES; POLYMERIC NANOPARTICLES; LIPOSOMAL DOXORUBICIN; SILVER NANOPARTICLES; CANCER-DIAGNOSIS;
D O I
10.1016/j.biopha.2019.108852
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Cancer continues to be the leading cause of death worldwide. Hepatocellular carcinoma (HCC), a prominent form of liver cancer, is the second leading cause of cancer-related deaths, thanks to the lack of efficient diagnostic tools and consequently late diagnosis and to the scarce of available suitable treatments. Thus, novel approaches to treat HCC are in demand. The fast-growing field of nanotechnology offers infinite possibilities to design materials in the nanoscale with unique properties due to their high surface area and small size. Nanotechnology enabled scientists to design drug delivery systems that serve multiple purposes including treatment, diagnostics and imaging. This review provides an update on the overall concept and potential of cancer nanotechnology; highlights the advances made particularly toward therapeutic nanomaterials targeting HCC. Obstacles hindering further development of nanomaterials -mediated cancer therapy will also be discussed.
引用
收藏
页数:12
相关论文
共 140 条
[91]   Implication of nano-antioxidant therapy for treatment of hepatocellular carcinoma using PLGA nanoparticles of rutin [J].
Pandey, Preeti ;
Rahman, Mahfoozur ;
Bhatt, Prakash Chandra ;
Beg, Sarwar ;
Paul, Basudev ;
Hafeez, Abdul ;
Al-Abbasi, Fahad A. ;
Nadeem, Muhammad Shahid ;
Baothman, Othman ;
Anwar, Firoz ;
Kumar, Vikas .
NANOMEDICINE, 2018, 13 (08) :849-870
[92]  
Parat A, 2015, NANOMEDICINE-UK, V10, P977, DOI [10.2217/NNM.14.196, 10.2217/nnm.14.196]
[93]   Hepatocellular cancer: A guide for the internist [J].
Parikh, Sameer ;
Hyman, David .
AMERICAN JOURNAL OF MEDICINE, 2007, 120 (03) :194-202
[94]  
Parveen S, 2008, J DRUG TARGET, V16, P108, DOI [10.1080/10611860701794353, 10.1080/10611860701794353 ]
[95]   Mesoporous Silica Nanoparticles in Cancer Therapy: Relevance of the Targeting Function [J].
Pasqua, Luigi ;
Leggio, Antonella ;
Sisci, Diego ;
Ando, Sebastiano ;
Morelli, Catia .
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2016, 16 (09) :743-753
[96]   On/off-switchable anti-neoplastic nanoarchitecture [J].
Patra, Hirak K. ;
Imani, Roghayeh ;
Jangamreddy, Jaganmohan R. ;
Pazoki, Meysam ;
Iglic, Ales ;
Turner, Anthony P. F. ;
Tiwari, Ashutosh .
SCIENTIFIC REPORTS, 2015, 5
[97]   MRI-Visual Order-Disorder Micellar Nanostructures for Smart Cancer Theranostics [J].
Patra, Hirak K. ;
Ul Khaliq, Nisar ;
Romu, Thobias ;
Wiechec, Emilia ;
Borga, Magnus ;
Turner, Anthony P. F. ;
Tiwari, Ashutosh .
ADVANCED HEALTHCARE MATERIALS, 2014, 3 (04) :526-535
[98]   Cancer cell response to nanoparticles: criticality and optimality [J].
Patra, Hirak Kumar ;
Dasgupta, Anjan Kr. .
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2012, 8 (06) :842-852
[99]  
Poon RTP, 2009, EXPERT OPIN PHARMACO, V10, P333, DOI [10.1517/14656560802677874 , 10.1517/14656560802677874]
[100]   In vitro and in vivo suppression of hepatocellular carcinoma growth by chitosan nanoparticles [J].
Qi, Lifeng ;
Xu, Zirong ;
Chen, Minli .
EUROPEAN JOURNAL OF CANCER, 2007, 43 (01) :184-193